Indivior Pharmaceuticals, Inc.

Drug pipeline (7)

Asset	Stage	Revenue	Trials	Status
Buprenorphine	approved	—	19	approved
Buprenorphine hydrochloride	approved	—	3	approved
Nalmefene hydrochloride	approved	—	0	—
NALOXONE HYDROCHLORIDE	approved	—	0	—
Risperidone	approved	—	68	approved

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (42)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT02511886	phase2	completed	2015-09-01	2016-01-01	Indivior Inc.	A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder
NCT03058237	phase1	completed	2017-01-24	2017-07-05	Indivior Inc.	A Phase 1 Bioavailability Study of Arbaclofen Placarbil Modified Release Formulations in Healthy Volunteers
NCT00605033	phase4	completed	2008-03-01	2009-04-01	Indivior Inc.	A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED)
NCT01846481	phase2	completed	2013-04-01	2013-06-01	Indivior Inc.	A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse
NCT00838396	phase2	completed	2005-10-01	2006-08-01	Indivior Inc.	A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease

FDA applications (7)

Application

Type

Applicant

Products

NDA 018401

NDA

INDIVIOR INC

NDA 020732

NDA

INDIVIOR INC

NDA 020733

NDA

INDIVIOR INC

NDA 022410

NDA

INDIVIOR INC

NDA 209819

NDA

INDIVIOR INC